Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025:2920:279-293.
doi: 10.1007/978-1-0716-4498-0_16.

Profiling Antibody Reactivity to Gut Microbes in ME/CFS Patients

Katharine A Seton  1 , Simon R Carding  2   3
Affiliations

Profiling Antibody Reactivity to Gut Microbes in ME/CFS Patients

Katharine A Seton et al. Methods Mol Biol. 2025.

Abstract

The gut microbiome plays a vital role in physiological functions including metabolism, immune regulation, and gut-brain communication. Alterations in gut microbe makeup and function, termed microbial dysbiosis, are associated with various metabolic, inflammatory, and neurological disorders. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients often display gut microbial dysbiosis and increased intestinal barrier permeability ("leaky gut"). This "leaky gut" allows for microbial products and toxins, such as lipopolysaccharides (LPS), to enter the bloodstream, triggering systemic inflammation and immune dysregulation. ME/CFS patients exhibit altered immune responses, including production of antibodies reactive with gut microbial antigens, although the significance of these antibodies in promoting pathogenic or protective immune responses remains unclear. This chapter outlines methodologies for quantifying antibody reactivity to intestinal microbes and identifying stool-bound IgG in ME/CFS patients and healthy same household controls, to further investigate the role of anti-microbial IgG in ME/CFS pathogenesis.

Keywords: Chronic fatigue syndrome; ELISA; Flow cytometry; IgA; IgG; IgG-Seq; Microbes; Microbiome; Myalgic encephalomyelitis.

PubMed Disclaimer

References

    1. Hou K, Wu Z-X, Chen X-Y, Wang J-Q et al (2022) Microbiota in health and diseases. Signal Transduct Target Ther 7:135. https://doi.org/10.1038/s41392-022-00974-4 - DOI - PubMed - PMC
    1. Madhogaria B, Bhowmik P, Kundu A (2022) Correlation between human gut microbiome and diseases. Inf Med 1:180–191. https://doi.org/10.1016/j.imj.2022.08.004 - DOI
    1. Hrncir T (2022) Gut microbiota dysbiosis: triggers, consequences, diagnostic and therapeutic options. Microorganisms 10. https://doi.org/10.3390/microorganisms10030578
    1. Zhao M, Chu J, Feng S et al (2023) Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: a review. Biomed Pharmacother 164:114985. https://doi.org/10.1016/j.biopha.2023.114985 - DOI - PubMed
    1. Carding S, Verbeke K, Vipond DT et al (2015) Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 26:26191. https://doi.org/10.3402/mehd.v26.26191 - DOI - PubMed

MeSH terms

LinkOut - more resources